Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Adolescence
13%
Alopecia Areata
12%
Arteriovenous Malformation
16%
Atopic Dermatitis
17%
Capillary
17%
Capillary Hemangioma
95%
Clinical Decision Making
10%
Congenital Malformation
22%
COVID-19
32%
Dermatitis
11%
Dermatological Agent
15%
Dermatology
18%
Dermatomyositis
9%
Diseases
12%
Eczema
18%
Folliculitis
9%
Hamartoma
25%
Hemangioendothelioma
9%
Hemangioma
66%
Infancy
16%
Infection
15%
Involution
16%
Juvenile Dermatomyositis
16%
Lupus Erythematosus Panniculitis
17%
Malformation Syndrome
9%
Myositis
16%
Neonates
17%
Neurofibromatosis Type I
16%
Nevus
12%
Oral
14%
Papule
13%
Pediatric Dermatology
17%
Pediatrician
10%
Pediatrics
34%
Pediatrics Patient
27%
Polymyositis
9%
Propranolol
28%
Psoriasis
10%
Rapamycin
32%
Rapidly Involuting Congenital Hemangioma
22%
Rituximab
19%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Skin Manifestation
16%
Subacute Cutaneous Lupus Erythematosus
16%
Trametinib
16%
Tumor
14%
Vascular Anomaly
19%
Vascular Tissue Neoplasm
19%
Vasculitis
10%
Venous Ulcer
25%
Keyphrases
Airway
12%
Arteriovenous Malformation
16%
Atopic Dermatitis
42%
Bleeding
10%
Blister
12%
Caregivers
10%
Clinical Decision-making
10%
Clinical Features
15%
Congenital Hemangioma
25%
Core Set Measures
14%
COVID-19
27%
Cutaneous Findings
19%
Cutaneous Lupus Erythematosus
16%
Cutaneous Reaction
16%
Dermatological Diseases
13%
Dermatologist
12%
Disfigurement
10%
Dupilumab
16%
European League against Rheumatism (EULAR)
16%
Hemangioma
32%
Infantile Hemangioma
100%
Involute
12%
Involution
14%
Juvenile Dermatomyositis
16%
Macules
12%
Myositis
13%
Natural History
22%
Neonate
17%
Neurofibromatosis Type 1 (NF-1)
16%
Noninvoluting Congenital Hemangioma
10%
Oral Propranolol
14%
Pediatric
21%
Pediatric Dermatology
19%
Pediatric Patients
25%
Pediatricians
11%
Propranolol
24%
Quality of Life
11%
Rapidly Involuting Congenital Hemangioma
24%
Reactive Infectious mucocutaneous Eruption
16%
Response Criteria
11%
Retrospective Review
16%
Rituximab
19%
Sirolimus
15%
Subcutis
10%
Systemic Therapy
12%
Topical Sirolimus
24%
Trametinib
16%
Vascular Anomalies
20%
Vascular Tumor
17%
Vasculitis
10%
